Novel |
ANXA1 |
annexin A1 |
- G alpha (q) signalling events
- G alpha (i) signalling events
- Formyl peptide receptors bind formyl peptides and many other ligands
- Smooth Muscle Contraction
- Interleukin-4 and Interleukin-13 signaling
- Developmental Lineage of Pancreatic Ductal Cells
|
- Amcinonide
- Fluocinolone acetonide
- Hydrocortisone
- Methylprednisolone
- Clobetasol propionate
- Budesonide
- Dexamethasone
- Cortisone acetate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
|
|
Novel |
APBB1 |
amyloid beta precursor protein binding family B member 1 |
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
|
Novel |
CEBPA |
CCAAT enhancer binding protein alpha |
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of granulopoiesis
- Transcriptional regulation of granulopoiesis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
- Acute myeloid leukemia (AML)
|
Novel |
CETN2 |
centrin 2 |
- Regulation of PLK1 Activity at G2/M Transition
- SUMOylation of DNA damage response and repair proteins
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- AURKA Activation by TPX2
|
|
|
Novel |
CRYAA |
crystallin alpha A |
|
|
|
Novel |
CSNK2A1 |
casein kinase 2 alpha 1 |
- Synthesis of PC
- WNT mediated activation of DVL
- Condensation of Prometaphase Chromosomes
- Signal transduction by L1
- Regulation of TP53 Activity through Phosphorylation
- Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
- Receptor Mediated Mitophagy
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Regulation of PTEN stability and activity
- KEAP1-NFE2L2 pathway
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
- Maturation of hRSV A proteins
- SPOP-mediated proteasomal degradation of PD-L1(CD274)
- Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
- ATP
- (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
- 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
- Resveratrol
- 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
- Benzamidine
- 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
- Quercetin
- Phosphoaminophosphonic Acid-Adenylate Ester
- Tetrabromo-2-Benzotriazole
- DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
- S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
- Emodin
- 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
- 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
- N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
- 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
- N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
- Dichlororibofuranosylbenzimidazole
- Quinalizarin
- Ellagic acid
- Fostamatinib
|
|
Novel |
DSCR9 |
Down syndrome critical region 9 |
|
|
|
Novel |
DUX4 |
double homeobox 4 |
- Zygotic genome activation (ZGA)
- Zygotic genome activation (ZGA)
|
|
|
Novel |
ESR1 |
estrogen receptor 1 |
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- RUNX1 regulates estrogen receptor mediated transcription
- ESR-mediated signaling
- RUNX1 regulates transcription of genes involved in WNT signaling
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
- Mitochondrial unfolded protein response (UPRmt)
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated estrogens
- Desogestrel
- Levonorgestrel
- Progesterone
- Lindane
- Raloxifene
- Toremifene
- Medroxyprogesterone acetate
- Testosterone
- Mitotane
- Estrone
- Tamoxifen
- Hexachlorophene
- Estradiol
- Ethynodiol diacetate
- Dobutamine
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinylestradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Oxybenzone
- Allylestrenol
- Zinc
- Genistein
- Prasterone
- Benzophenone
- Equilin
- Compound 19
- Resveratrol
- Compound 18
- Phthalic Acid
- Pyrazole
- Stanolone
- Naringenin
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Quercetin
- Afimoxifene
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estrone sulfate
- Quinestrol
- Phenolphthalein
- Permethrin
- Ospemifene
- AP1081
- Custirsen
- NP-50301
- CHF 4227
- TAS-108
- Lasofoxifene
- Arzoxifene
- Elacestrant
- Bazedoxifene
- Methyltestosterone
- beta-Naphthoflavone
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- din-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- Hexestrol
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- Erteberel
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
- Tibolone
- Eugenol
- Synthetic Conjugated Estrogens, A
- Synthetic Conjugated Estrogens, B
- Polyestradiol phosphate
- Norethynodrel
- Octocrylene
- Homosalate
- Enzacamene
- Zeranol
- Ractopamine
- Gestrinone
- Estetrol
- Propyl Gallate
- Ormeloxifene
- 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
- Testosterone cypionate
- Testosterone enanthate
- Stanolone acetate
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
- Estriol tripropionate
- Fluoroestradiol F-18
|
|
Novel |
GABRE |
gamma-aminobutyric acid type A receptor subunit epsilon |
|
- Lorazepam
- Ethchlorvynol
- Enflurane
- Temazepam
- Butabarbital
- Butalbital
- Phenytoin
- Etomidate
- Talbutal
- Pentobarbital
- Clobazam
- Meprobamate
- Eszopiclone
- Alprazolam
- Metharbital
- Chlordiazepoxide
- Amoxapine
- Adinazolam
- Lamotrigine
- Medroxyprogesterone acetate
- Clorazepic acid
- Midazolam
- Flurazepam
- Isoflurane
- Primidone
- Halazepam
- Propofol
- Diazepam
- Oxazepam
- Triazolam
- Ethanol
- Methoxyflurane
- Memantine
- Clonazepam
- Methyprylon
- Halothane
- Desflurane
- Flumazenil
- Estazolam
- Sevoflurane
- Glutethimide
- Camazepam
- Delorazepam
- Flunitrazepam
- Ethyl loflazepate
- Cloxazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Ketazolam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
- Prasterone
- Taurine
- Ganaxolone
- Brotizolam
- Stiripentol
- Etizolam
- Thiocolchicoside
- Brexanolone
- Apalutamide
- Remimazolam
- 1,2-Benzodiazepine
- Pinazepam
- Medazepam
- Loprazolam
- Doxefazepam
- Lormetazepam
- Nordazepam
- Oxazepam acetate
- Cinazepam
- Bentazepam
- Mexazolam
|
|
Novel |
HNF4A |
hepatocyte nuclear factor 4 alpha |
- Nuclear Receptor transcription pathway
- Nephron development
|
- Lauric acid
- AVI-4557
- Myristic acid
|
- Maturity onset diabetes of the young (MODY)
|
Novel |
IKBKE |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
- SUMOylation of immune response proteins
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TICAM1-dependent activation of IRF3/IRF7
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- SARS-CoV-1 activates/modulates innate immune responses
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
- Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
|
|
Novel |
IL7R |
interleukin 7 receptor |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
Novel |
LINC01232 |
long intergenic non-protein coding RNA 1232 |
|
|
|
Novel |
LINC01554 |
long intergenic non-protein coding RNA 1554 |
|
|
|
Novel |
MAVS |
mitochondrial antiviral signaling protein |
- DDX58/IFIH1-mediated induction of interferon-alpha/beta
- Ovarian tumor domain proteases
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- Negative regulators of DDX58/IFIH1 signaling
- Negative regulators of DDX58/IFIH1 signaling
- SARS-CoV-1 activates/modulates innate immune responses
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Evasion by RSV of host interferon responses
- PKR-mediated signaling
|
|
|
Novel |
MIR1-1 |
microRNA 1-1 |
|
|
|
Novel |
MIR1-2 |
microRNA 1-2 |
|
|
|
Novel |
MIR106A |
microRNA 106a |
|
|
|
Novel |
MIR106B |
microRNA 106b |
|
|
|